Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders.

Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders.
复制标题

DOI:
10.1016/j.molmed.2010.10.002
复制
发表时间:
2011-02
影响因子:
13.6
通讯作者:
Silva AJ
Silva AJ
中科院分区:
医学1区
文献类型:
--
作者:
Ehninger D;Silva AJ

文献摘要

参考文献

被引文献

相似文献

结节性硬化症(TSC)是一种由TSC1或TSC2基因杂合突变引起的遗传性疾病,在20%-60%的病例中与自闭症谱系障碍(ASD)有关。此外,改变的TSC/mTOR信号正在成为ASD子集的共同特征。在动物模型中,最近的研究结果表明,即使在成年动物中开始治疗,修复潜在的分子缺陷也可以改善其中几种模型的神经功能障碍,这表明成熟脑中的病理生理过程对这些模型的整体神经表型有重要贡献。这些发现表明,ASD的治疗干预窗口可能比之前想象的更宽。
Tuberous sclerosis (TSC) is a genetic disorder caused by heterozygous mutations in the TSC1 or TSC2 genes and is associated with autism spectrum disorders (ASD) in 20–60% of cases. In addition, altered TSC/mTOR signaling is emerging as a feature common to a subset of ASD. Recent findings, in animal models, show that restoration of the underlying molecular defect can improve neurological dysfunction in several of these models, even if treatment is initiated in adult animals, suggesting that pathophysiological processes in the mature brain contribute significantly to the overall neurological phenotype in these models. These findings suggest that windows for therapeutic intervention in ASD may be wider than thought previously.
DOI: 10.1038/nn.2255
发表时间: 2009-02
影响因子: 25
作者:
Chow, David K.;Groszer, Matthias;Pribadi, Mochtar;Machniki, Michal;Carmichael, S. Thomas;Liu, Xin;Trachtenberg, Joshua T.
通讯作者: Trachtenberg, Joshua T.
DOI: 10.1016/0092-8674(94)90214-3
发表时间: 1994-05-20
期刊: CELL
影响因子: 64.5
作者:
BRILLANTES, AMB;ONDRIAS, K;MARKS, AR
通讯作者: MARKS, AR
DOI: 10.1007/s00787-006-0570-3
发表时间: 2007-02-01
影响因子: 6.4
作者:
de Vries, Petrus J.;Hunt, Ann;Bolton, Patrick F.
通讯作者: Bolton, Patrick F.
DOI: 10.1097/dbp.0b013e31817dc447
发表时间: 2008-08-01
影响因子: 2.4
作者:
Berry-Kravis, Elizabeth;Sumis, Allison;Greenough, William T.
通讯作者: Greenough, William T.
DOI: 10.1093/brain/awf124
发表时间: 2002-06-01
期刊: BRAIN
影响因子: 14.5
作者:
Bolton, PF;Park, RJ;Pickles, A
通讯作者: Pickles, A